Figure 3
Figure 3. Podoplanin-Fc suppresses lymphangiogenesis in inflamed mouse corneas in vivo. (A) Representative whole-mount micrographs of corneal lymphatic vessels, visualized by immunofluorescent staining for the lymphatic marker LYVE-1 (red) after 2 weeks of treatment with human IgG or podoplanin-Fc (100 μg, injected every second day into subconjunctival space). Original magnification ×25. White circle: demarcation between the cornea and conjunctiva. (B) Summary of lymphatic vascular scores, determined for each cornea based on the circumferential extent and centripetal growth of lymphatic vessels. Data represent mean ± standard error of the mean (nIgG = 10, nPdpn-Fc = 7), * P < .05. (C) Representative micrographs of corneal lymphatic vessels double-stained for LYVE-1 (green) and Prox-1 (red). Original magnification ×400.

Podoplanin-Fc suppresses lymphangiogenesis in inflamed mouse corneas in vivo. (A) Representative whole-mount micrographs of corneal lymphatic vessels, visualized by immunofluorescent staining for the lymphatic marker LYVE-1 (red) after 2 weeks of treatment with human IgG or podoplanin-Fc (100 μg, injected every second day into subconjunctival space). Original magnification ×25. White circle: demarcation between the cornea and conjunctiva. (B) Summary of lymphatic vascular scores, determined for each cornea based on the circumferential extent and centripetal growth of lymphatic vessels. Data represent mean ± standard error of the mean (nIgG = 10, nPdpn-Fc = 7), * P < .05. (C) Representative micrographs of corneal lymphatic vessels double-stained for LYVE-1 (green) and Prox-1 (red). Original magnification ×400.

Close Modal

or Create an Account

Close Modal
Close Modal